As of August 1, 2026, the Democratic Republic of the Congo has recorded 3,748 cases of Ebola, resulting in 1,657 deaths and 708 recoveries, marking the largest outbreak in the nation's history. This human toll continues to mount while a clinical trial for a potential oral post-exposure prophylaxis medicine is just now underway in Ituri province.
The Human Cost
The trial, led by the DRC's National Institute for Biomedical Research and an international consortium, has enrolled over 25 patients. These patients are confirmed high-risk contacts, receiving an oral medicine for 10 days to assess its ability to prevent disease onset. The World Health Organization (WHO) stated on Tuesday that definitive results from these trials may be months away.
The current outbreak, declared in mid-May 2026, continues its spread. Despite efforts toward enhanced treatment and the world's first vaccine for the Bundibugyo species of Ebola, the WHO confirms there are still no proven safe and efficacious treatment, preventive, or vaccination options for this specific strain. This lack leaves the most vulnerable populations exposed to a deadly pathogen.
Profits and Delays
Trials for a Bundibugyo species-specific candidate vaccine began in the UK on July 24, 2026, with a second starting in Canada this week. Both trials are currently being conducted on ferrets and monkeys, a necessary but time-consuming phase before human trials can even be considered. WHO's R&D Blueprint acting lead, Vasee Moorthy, noted that protocols were written before the current outbreak was declared, allowing for quicker trial starts than in previous Ebola outbreaks. Yet, he anticipates several months before any definite conclusions can be drawn.
This timeline highlights the systemic delays in bringing life-saving interventions to the populations most affected. While new data from animal studies on the licensed Ervebo vaccine, which targets a different Ebola strain, has emerged, its relevance to the current Bundibugyo outbreak remains limited. The UN health agency's technical advisory group convened last Friday, 2026, and is expected to publish recommendations later this week, but these are advisory, not immediate solutions.
The State's Role and Limited Aid
In Bunia, the capital of Ituri, a new 100-bed treatment center was inaugurated. Dr. Moorthy also reported that three testing sites have opened in Ituri province since the outbreak was declared, with a fourth set to open later this week. These sites aim to enroll patients in trials and monitor them under safe conditions, but the process of ramping up enrollment is slow, requiring "more and more teams and more sites."
The UN refugee agency, UNHCR, provides support for screening, infection prevention, risk communication, and essential hygiene items. At the DRC-Uganda border, a mobile lab, supported by WHO and the World Food Programme, delivers Ebola test results in about one hour, serving over 94,000 people. UNICEF operates nurseries for children from Ebola-affected families, addressing the immediate social fallout.
The MONUSCO peacekeeping mission in the DRC, often acting as an imperial garrison, protects civilians and conducts information campaigns. It has increased its presence around medical facilities, ostensibly to support WHO teams and partners. The UN aid coordination office OCHA is releasing up to $60 million from the UN's Global Emergency Fund, CERF, to support response and preparedness efforts in the DRC and neighboring countries. These measures, while providing some relief, do not fundamentally alter the structural conditions that allow such outbreaks to devastate communities, nor do they accelerate the development and deployment of proven treatments to those who need them most. The underlying issue remains the slow pace of capital-driven research and the reactive nature of international aid, leaving the working class in the DRC to bear the brunt of the crisis.